FIELD: biotechnology.
SUBSTANCE: what is described is a method for selecting a subject suffering from cancer for applying a therapeutic regimen comprising administering a pharmaceutical composition containing an effective amount of an FGFR inhibitor, said method comprising: (1) obtaining a tumor biopsy or a liquid biopsy from said subject; (2) determining the expression level of any one or all of FGFR1, FGFR2 and FGFR3; and (3) comparing said determined expression level of at least one of FGFR1, FGFR2 and FGFR3 with a predetermined threshold value and identifying said subject as suitable for using said treatment regimen, in case said specified level exceeds specified threshold level.
EFFECT: present invention also relates to a method for personalized cancer therapy comprising selecting a subject according to the above method and applying a therapeutic regimen to said patient, which involves administering a pharmaceutical composition containing an effective amount of an FGFR inhibitor.
35 cl, 7 tbl, 2 ex, 11 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF INHIBITOR FGFR AND INHIBITOR IGF1R | 2015 |
|
RU2715893C2 |
| PTERIDINES AS FGFR INHIBITORS | 2013 |
|
RU2702906C2 |
| COMBINATIONS | 2015 |
|
RU2715236C2 |
| BIGETEROARYL-SUBSTITUTED 1,4-BENZODIAZEPINES AND WAYS OF THEIR USE FOR CANCER TREATMENT | 2016 |
|
RU2747644C2 |
| NEW COMPOUNDS | 2016 |
|
RU2747645C2 |
| QUINAZOLINONE DERIVATIVES APPLICABLE AS MODULATORS OF FGFR KINASE | 2014 |
|
RU2701517C2 |
| SUBSTITUTED QUINAZINE DERIVATIVES AS FGFR-KINASE INHIBITORS FOR TREATMENT OF CANCER | 2011 |
|
RU2602233C2 |
| QUINOLINES AS FGFR KINASE MODULATORS | 2012 |
|
RU2625303C2 |
| FIBROBLAST GROWTH FACTOR RECEPTOR EXTRACELLULAR DOMAIN ACIDIC REGION MUTEINS | 2009 |
|
RU2509774C2 |
| DERIVATIVES OF 1,5- AND 1,7-NAPHTHYRIDINE USEFUL IN TREATMENT OF FGFR-MEDIATED DISEASES | 2012 |
|
RU2629194C2 |
